2022
DOI: 10.1093/ced/llac117
|View full text |Cite
|
Sign up to set email alerts
|

Genetic findings in a patient with paradoxical pyoderma gangrenosum induced by brodalumab

Abstract: We describe a patient with psoriasis who developed pyoderma gangrenosum while on treatment with brodalumab, an anti-interleukin (IL)-17 receptor monoclonal antibody. Genetic analyses revealed heterozygous polymorphisms within the promoter region of the IL-6 (promoter polymorphism –174 G/C) and IL-10 genes (promoter polymorphism –1082 A/G).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 6 publications
0
1
0
Order By: Relevance
“…36 IL-6 upregulation has been reported in gene expression studies of PG, which provides a plausible pathogenesis for PG in XLA. 26,[37][38][39] IL-6 favours T H 17 differentiation promoting the downstream elevation of cytokines reported in PG (e.g. IL-23).…”
Section: X-linked Agammaglobulinemiamentioning
confidence: 99%
“…36 IL-6 upregulation has been reported in gene expression studies of PG, which provides a plausible pathogenesis for PG in XLA. 26,[37][38][39] IL-6 favours T H 17 differentiation promoting the downstream elevation of cytokines reported in PG (e.g. IL-23).…”
Section: X-linked Agammaglobulinemiamentioning
confidence: 99%